View the 2017 Conference program booklet

Keynote Speakers:


Dr. Roger Glass, MD, PhD, MPH

Presentation: Global Health – Urgency, Importance and Priorities

Dr. Glass was named director of the Fogarty International Center and Associate Director for International Research by NIH Director Elias A. Zerhouni, M.D., on March 31, 2006. Dr. Glass graduated from Harvard College in 1967, received a Fulbright Fellowship to study at the University of Buenos Aires in 1967, and received his M.D. from Harvard Medical School and his M.P.H. from the Harvard School of Public Health in 1972. He joined the Centers for Disease Control and Prevention in 1977 as a medical officer assigned to the Environmental Hazards Branch. He was a Scientist at the International Center for Diarrheal Disease Research in Bangladesh from 1979-1983 and returned to Sweden where he received his doctorate from the University of Goteborg. In 1984, he joined the National Institutes of Health Laboratory of Infectious Diseases, where he worked on the molecular biology of rotavirus. In 1986, Dr. Glass returned to the CDC to become Chief of the Viral Gastroenteritis Unit at the National Center for Infectious Diseases. Dr. Glass’s research interest are in the prevention of gastroenteritis from rotaviruses and noroviruses through the application of novel scientific research. He has maintained field studies in India, Bangladesh, Brazil, Mexico, Israel, Russia, Vietnam, China and elsewhere. His research has been targeted toward epidemiologic studies to anticipate the introduction of rotavirus vaccines. He is fluent and often lectures in five languages.

Dr. Nubia Miñoz, MD, MPH

Presentation: HPV Vaccination: From Discovery to Vaccine Impact and

Vaccine Hesitance

Dr. Nubia Muñoz is a Colombian scientist graduated from the School of Medicine at Universidad de Valle in 1964. After graduation from Universidad del Valle, she worked for three years in the National Cancer Institute in Bethesda, where the headquarters of the National Health Institute is located. She got a Master’s Degree in Public Health specializing in Epidemiology and Virology of Cancer in the School of Public Health of John Hopkins University in Baltimore. Then, she went to Lyon, France, to continue her research at the International Agency for Research of Cancer (IARC), which belongs to the World Health Organization. Nubia Muñoz is a former winner of the First Richard Doll Prize in Epidemiology for proving the HPV causes Cervical Cancer. Her story is a remarkable one and will undoubtedly go down in the annals of epidemiology as an example par excellence of what all epidemiologists aspire to and can accomplish in studying the etiology of a disease. Dr. Muñoz was a Postgraduate student, School of Public Health, 1968 to 1969, at John Hopkins. Dr. Muñoz work at the International Agency for Research on Cancer in Lyon, France, and with teams across the world led to establishing the relationship between the human papillomavirus and cervical cancers. This recognition of a viral cause of cervical cancer has led to the development of vaccines that would prevent these infections and that hold promise for the control and possible elimination of this cancer.

Dr. Marcos Espinal, MD, MPH, PhD

Presentation: The 21st Century Threat to Public Health — Rapidly Evolving

Antimicrobial Resistant Organisms

Dr. Marcos Espinal is chief of the Department of Communicable Diseases and Health Analysis at the WHO’s Pan American Health Organization (PAHO) in Washington, D.C. He was previously executive secretary of the WHO’s Stop TB program and earlier held positions in the Dominican Republic’s Ministry of Health. Espinal trained as a pediatrician in the program and earlier held positions in the Dominican Republic’s Ministry of Health. Dr. Espinal trained as a pediatrician in the Dominican Republic and, starting in 1989, pursued his master’s and doctoral degrees at the University of California, Berkeley with support from Fogarty’s flagship AIDS research and training program. He has published more than 100 papers about communicable diseases. Dr. Espinal’s work experience includes positions in the Ministry of Health of the Dominican Republic and the National Center for Research on Maternal and Child Health; the New York City Public Health Department; and the WHO. Before joining PAHO, Dr. Espinal served as Executive Secretary of the WHO Stop TB Partnership, a global movement aiming at the elimination of TB as a public health problem. Dr. Espinal has published more than 100 publications in the field of communicable diseases and is a recipient of the Scientific Prize of the International Union against Tuberculosis and Lung Disease, the Albert and Mildred Krueger Memorial Fellowship, and a graduate scholarship from the John E. Fogarty International Center. In 2008, the University of California at Berkeley awarded Dr. Espinal the Walter and Elise A. Hass International Award for a distinguished record of service in international health; and in 2012, he was awarded the Princess Chichibu Memorial TB Global Award by the Japan Anti-Tuberculosis Association.


We would like to thank our sponsors for the 2017 Conference:


Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, we transform scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 110,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.


Merck is an innovative, global healthcare leader that is committed to improving health and well-being around the world.

Our core product categories include diabetes, cancer, vaccines and hospital acute care. We continue to focus our research on conditions that represent some of today’s most significant health challenges – like cancer, hepatitis C, cardio-metabolic disease, antibiotic-resistant infection and Alzheimer’s disease, and we are on the front lines in the fight against emerging global pandemics, such as ebola.

We also devote extensive time and energy to increasing access to medicines and vaccines through far-reaching programs that donate and deliver our products to the people who need them.

At Merck, we’re applying our global reach, financial strength and scientific excellence to do more of what we’re passionate about: improving health and improving lives.


Oxitec is a pioneer in controlling insects that spread disease and damage crops.

Through world class science we have developed an innovative new solution to controlling harmful insects pests. Our solution can help governments and communities around the world keep people healthy and increase food production, and to do so in a way which is sustainable, environmentally friendly and cost effective.

Oxitec is a subsidiary of Intrexon Corporation (NYSE: XON), which engineers biology to help solve some of the world’s biggest problems.